We use a Molecular Pharming technology to develop plant-based vaccines. We designed the protein of SARS-CoV-2 virus and let plants produce the protein that has similar shape of the viral protein. The plant produced-protein will be delivered into the body to allow the body creating a specific immune system against the COVID-19 virus. This technology is used in vaccine production in several countries.

          The vaccines produced by Baiya Phytopharm can stored at 2-8 °C in 2 month. The advantages of this technology is the rapid production, therefore it can be easily developed if COVID continues to mutate in the future.

          Baiya Phytopharm began the vaccine development in February 2020. Our first vaccine candidate, Baiya SARS-CoV-2 Vax 1, is successfully tested in animal studies (mice and monkeys). the results show that the vaccine boosts the level of antibodies in the test animals effectively after just two doses.

               Basically, vaccine development must be tested in animal and human prior to release. Baiya planned to complete all phases of human trials by 2021 and produce for general use by 2022. Hopefully this will be the vaccine of choice for all Thai people to have enough vaccines against COVID-19.

               We need a further study to ensure how long the shot last and the percentage of protection. However, the results from animal studies show that the vaccine boosts the level of antibodies effectively after two doses, 21 days apart.

               The safety of Baiya’s plant-based vaccine are currently available only in mice and monkeys. None of the serious adverse events and death were found in animal testing. Although we need further study in human which planned to launch by 2021 to ensure the safety of the vaccine.